Patrick Shea joins Egalet as Chief Commercial Officer

He will be responsible for developing and implementing the firm's commercialisation strategy

Egalet, a developer of treatments for pain and other conditions, has hired Patrick Shea as Chief Commercial Officer (CCO).

Shea will be responsible for leading Egalet's commercial activities and will report to Bob Radie, Chief Executive Officer.

In his role he will develop and implement the commercialisation strategy for Oxaydo (oxycodone HCI, USP) tablets for oral use only, Sprix (ketorolac tromethamine) nasal spray, Arymo ER (morphine sulfate) extended-release tablets, which are under review at the US Food and Drug Administration and additional Guardian Technology pipeline products as they are developed.

He has more than two decades of sales, marketing, market access and commercial operations experience.

Most recently he was CCO at Clarus Therapeutics, a men's health speciality pharmaceutical company.

Prior to this he was Vice President of Sales and Marketing for the US commercial operations of CSL Behring.

Before that he was Senior Vice President of Sales and Marketing for the US pharmaceutical operations at Astellas Pharmaceuticals, and held senior sales and marketing roles at Ligand Pharmaceuticals and Boehringer Ingelheim.

You may also like

Research & Development

Egalet terminates collaboration with Shionogi

Gains worldwide rights to Phase ! abuse-deterrent, extended-release hydrocodone product candidate
Research & Development

Egalet to collaborate with Shionogi to develop abuse-deterrent oral hydrocodone opioid product candidates

Will receive upfront and milestone payments plus potential royalties on net sales
Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Manufacturing

Leybold launches Duradry vacuum pump for harsh processes

Advanced technology designed for reliability and efficiency
Subscribe now